The U.S. Food and Drug Administration has given Teva Pharmaceutical Industries Ltd.'s (TEVA) a shot in the arm.

Teva's American depositary receipts shot up on Thursday, Aug. 16, after the FDA approved a generic version of Mylan NV's (MYL) EpiPen auto-injector for treating allergic reactions. Teva's ADRs finished the trading session at $24.11, up 7.3%.

The FDA will allow Teva Pharmaceuticals USA to sell its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.

"This represents the first true generic version of EpiPen approved by the agency, as Mylan markets its own authorized generic and Amneal's epinephrine autoinjector is a BX rated version," Leerink Partners LLC analyst Ami Fadia wrote in a note. The BX rating for Amneal Pharmaceuticals Inc.'s (AMRX) version means that data reviewed by the FDA were not enough to determine therapeutic equivalence.

Shares of Mylan on Thursday closed at $37.85, up 0.08%. Amneal's sharesfell 1.4% to $21.63.

The near-term competitive landscape is "certainly favorable for Teva, as both Mylan and Amneal have experienced inconsistent supply on their products throughout the year," Fadia wrote.

More from Markets

Fossil Shares Rise After Company Announces Plan to Sell Tech to Google

Fossil Shares Rise After Company Announces Plan to Sell Tech to Google

Netflix Shares Fall After Company Reports Mixed Earnings Results

Netflix Shares Fall After Company Reports Mixed Earnings Results

3 Things to Know at the Market Close: Bank Earnings, GDP Report and Jim Cramer

3 Things to Know at the Market Close: Bank Earnings, GDP Report and Jim Cramer

Morgan Stanley Sinks as Profit Misses Estimates Amid Trading Slump

Morgan Stanley Sinks as Profit Misses Estimates Amid Trading Slump

IBM to Run Vodafone's Cloud Business, Offer Solutions to Its European Customers

IBM to Run Vodafone's Cloud Business, Offer Solutions to Its European Customers